Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lets revisit where we are at the end of this week. In theory, we should at least be higher than last Friday's close. But I would not be surprised to see us trading at below $2.40. I hope I am wrong, but I think the games will continue.
Samsa- I am guessing the wash trading and short selling will continue to erode this back down to where it started. They will blame it on earnings report and no partner for Seroquel. We should be solidly above $3 but the games will continue...
Impact- I agree... IPCI is in the drivers seat in this partner negotiation. They have the tentative approval and they paid all development costs. They will be able to launch Seroquel after the 180 day exclusivity period. This is not Keppra... They have people knocking on their door to license this Seroquel. I know people on here have talked about package deals recently. I am thinking that is a possibility. I could see the same company licensing Seroquel and Keppra and maybe even other ANDAs.
I know some of the naysayers at first said that the only reason Focalin made it was because Par babysat it through. IPCI has once again validated itself with another approval!
Angelo- Your comment is too funny... But I do suspect it is true to some extent.
Good luck fishing Angelo! Are you fishing for Salmon?? I hope the winds are down for you but this time of year you never know.
Numbers- There was a suspicious increase in volume the last couple weeks. That does suggest some people knew the approval was coming. Unlike the Keppra approval- this is a significant approval... It is unfortunate that some are gaining access to this info early and cashing in. Hopefully the SEC reviews some of the trade records but I am not holding my breath...
I must admit that I did not think they would get Seroquel approval in first round. I felt that way as they are not a first filer. But I could not be happier that I was wrong! This is the biggest ANDA approval IPCI could have gotten. Potential partners are lining up as we speak. I would not be surprised if Penna will be fielding calls from potential suitors this weekend. Chalk one up for IPCI... They are in the drivers seat on this one and as we speak there are companies drooling over getting their meat hooks on that approval. However, this one will come at a price to these companies... IPCI footed the development bill and babysat the filing and now its time to cash in. Don't be surprised if this partnership turns into a multi-drug deal either. What companies out there do not have a version of Keppra and Seroquel?
Short interest is just above 6%. In my opinion, that is pretty low for this kind of stock.
Samsa- The call volume was through the roof today. The Put to Call ratio is on the order of 0.05... Which means everyone is betting on higher prices!
Samsa- I am thinking the buyout is just rumor. I do however think we could hear about a partnership soon. My guess is Rexista/PODRAS partner, Rexista NDA filing and PODRAS patent official announcement. I am guessing that is what could be coming down the pipe.
Frugal- good points.
Angelo- I agree that possibilities are endless. But my guess is a Rexista/PODRAS partnership soon, Rexista NDA filing and PODRAS official patent approval. I believe that could be what is happening and driving stock. My guess is partner is TEVA. But these are all guesses. Yes, buyout is possible, but I am of the opinion that is likely not the case.
I agree that the after hours volume is a tell something is up. It is on track with daily volume...
TORONTO, Sept. 22, 2016 /CNW/ - The following issues have been halted by IIROC:
Company: IntelliPharmaCeutics International Inc.
TSX Symbol: I (all issues)
Reason: Pending Company Contact
Halt Time (ET): 2:53 PM ET
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
/CONTACT:
IIROC Inquiries 1-877-442-4322 (Option 2) - Please note that IIROC is not able to provide any additional information regarding a specific trading halt. Information is limited to general enquiries only.
/Web site: http://www.iiroc.ca/
Copyright CNW Group 2016
(END) Dow Jones Newswires
September 22, 2016 15:07 ET (19:07 GMT)
Weezuhl- Care to comment on how ELTP will be taking care of that CRL? Seems to me like ELTP has hit a road block with FDA and it is going to take a good amount of time to resolve this food effect issue.
Doog- What is your connection to Pharmer? How do you know each other?
When I said the rumor was first reported on IPCI.CA I meant it was where I saw the link to Briefing.com. As far as I know, the people on that board had nothing to do with the briefing.com report. It is just the location where I saw the link.
Sorry Angelo, everything I use is baitcasting.
Angelo- I just posted a link to an online rumor... No need to get so upset... Personally, I think it is good news to see IPCI mentioned in this way.
This rumor/link was first reported on IPCI.CA.
What does everyone think of IPCI buyout rumor posted here:
http://www.briefingwire.com/pr/potential-950-buyout-rumor-for-intellipharmaceutics
Samsa- I agree the patent is close to being issued. My guess is we hear something official within the next few weeks.
Angelo- We are on the same page on Seroquel.
Fabius- This has been obvious to me for some time...
Doog- Regarding the Seorquel approval. Since IPCI is not one of the first filers, my guess is they do not get approval in first round. That is only a guess on my part though. Anyone have any other opinions on this? I base this on my observation that the first round of Focalin and Pristiq approvals were pretty much limited to first filers.
Timing sure seems peculiar...
Angelo- What that tells me is that even most of the traders expect IPCI to file soon.
Trenches- I am not saying stating the manufacturer on NDA is or is not required. I do not know. I am just saying that instead of speculating and debating it, ask IPCI what they feel is required for the NDA and how they plan to handle it. Then let us know what they say in regards to this. I fully expect they understand this requirement and will handle it appropriately. But am curious to hear what they say.
In regards to a partner, I feel IPCI has been very clear that they will not partner Rexista until at least after the NDA submission.
Trenches- I look forward to hearing what company says.
Trenches- Give IPCI a call or an email and ask them what their opinion is on the manufacturer debate. Put this issue to rest. A lot of speculating can be put to rest by contacting IR. If it is privileged info they cannot tell you, but most items don't fall under privileged.
Incessant babbling I agree! That was a great way to put it!
I want everyone to be clear on one thing. They do not need a partner to file the Rexista NDA. Also, they will not have a partner when they file the Rexista NDA. The company has been very clear on how they will handle this.
Samsa- I agree. Get it done right even if it means filing a few days into September. And let the guys who want to short this down do it. I will be there to buy more. They can then cover at a higher price once the filing occurs.
I agree. Unless the guy gives some supportive evidence to back up his "talk" on Rexista not being abuse deterrent it is just that... Talk... I have seen that guy somewhere before and I also suspect ulterior motives.
The guy who wrote the article that said the end of this week made an error. The company communication said the end of August... I am expecting IPCI to file next week and make the end of August deadline. But it is going to be very tight. If they fall a few days short then so be it. What is most important is that they submit a quality application. It should be interesting to see if someone has balls of steel and tries to short this down. They would have to be very brave as the application is indeed coming soon!
Viking- I agree! They are doing their best to get this filed. I believe they will file soon. I expect August, but cannot guarantee they will make it. They will be close. What is more important is a quality filing as you alluded too!
Sprot- Yes the FDA will determine if the data provided shows bioequivalence. IPCI feels it does, but it is up to the FDA to make a call on this.
Sprot- I think you are wrong. I think the filing is coming very soon. My guess is it will be within August. And if late, only by a few days.
I think if you were to contact IPCI and ask about what they plan to do with Rexista, they would tell you they likely will partner. I know there has been talk on here about them doing something else... But I truly believe they intend to partner at an opportune time for the company. My guess on who the partner will be is TEVA. But that is just a guess based on things I have witnessed over the last couple of years.
Probably about the same time ELTP gives notice they need to run another clinical trial...